Revision History

California-based abortion pill suppliers and telehealth companies are preparing rapid workarounds — including switching to misoprostol-only regimens and invoking state shield laws — as the Supreme Court weighs whether to let a Fifth Circuit ruling stand that would reimpose in-person dispensing requirements for mifepristone nationwide. The case, Louisiana v. FDA, raises questions that extend well beyond abortion, threatening the FDA's authority over drug approval and potentially exposing vaccines, contraceptives, and other politically contested medications to similar legal challenges.